Telogen effluvium
Therapeutic area
Dermatology
Rare disease
No
- Definition
- A scalp hair loss condition characterized by excessive shedding of hair in the resting phase of growth, usually following a fever or major body stress.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Telogen effluvium
- Alternative names
- telogen effluvium
- Therapeutic area
- Dermatology
- All therapeutic areas
- Dermatology
- Severity
- Mild
- MONDO ID
- MONDO:0002153
- Parent condition
- MONDO:0004907
Related records
Broader conditions (8)
- Alopecia
- Disease
- Disease by body system or component
- Disorder of pilosebaceous unit
- Hair anomaly
- Human disease
- Integumentary system disorder
- Skin appendage disorder
Trials (15)
- A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
- A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
- BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.
- Clinical Evaluation of a Nutraceutical Supplement (Olistic Women) for Hair Growth and Hair Loss in Human Volunteers
- Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
- Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss.
- COVID-19 Induced Telogen Effluvium
- Demonstration of the Presence of a Carbonyl Stress in the Hair Follicles of Postpartum Women
- Efficacy and Safety of a Dietary Supplement on Hair Growth and Hair Health in Female With Acute Telogen Effluvium
- Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists
- Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment
- Efficacy Study of Cosmetic Product Against Telogen Effluvium on Women
- Evaluation of Tolerance and Trichological Efficacy of a Food Supplement
- PAI-1 Expression in Non-scarring Hair Loss
- Therapeutic Potential of Topical Latanoprost Acid in Hair Loss - Pilot, Proof-of-concept Study